In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.
|Webcasts|July 22, 2020
Accelerate your Clinical Trial by Adopting a New Mindset
Hear from industry experts, Chris Crabtree and Ben Thomas, on ways to accelerate trial completion by adopting a new way of operating and a more strategic engagement approach with investigators, coordinators and other trial stakeholders. Live Q&A to follow. Live: Wednesday, Jul. 22, 2020 at 10am EDT | 9am CDT | 3pm BST | 4pm BST On demand available after airing until Jul. 22, 2021. Register free
Register free:
Event Overview:
Trial enrollment has become increasingly more competitive leading to slower patient recruitment, lost commercial opportunity, and delays in bringing potential life-saving treatments to patients. Improvement in clinical trial enrollment is an urgent need across all therapeutic areas but requires a new way of operating to revitalize current practices. During this webcast we’ll discuss ways to accelerate trial completion through a more strategic engagement with investigators, coordinators and other trial stakeholders.
Key Learning Objectives:
- Explore a new way to think about, operate, and accelerate trial enrollment to get your new therapies to patients faster
- Learn how ZS’s Trial Launch Catalyst solution can assist with insights generation, segmentation, value messaging, and site-stakeholder engagement
- Discuss routes to integrate these practices into your work
Speakers: Chris Crabtree, Associate Principal, ZS
Ben Thomas, Strategy Insights & Planning Consultant, ZSS
Time and date: Wednesday, Jul. 22, 2020 at 10am EDT | 9am CDT | 3pm BST | 4pm BST
On demand available after airing until Jul. 22, 2021.
Sponsor: ZS
Register free:
Related to this article
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal
In today’s ACT Brief, we examine why community research needs lasting financing and infrastructure, how electronic outcome tools can strengthen neuroscience endpoints, and how Teva is licensing two biosimilars from Samsung Bioepis.
Neuroscience trials struggle to show benefit because symptoms are subjective and variable, and eCOA strengthens dossiers by standardizing ClinRO administration, capturing outcomes in real time to reduce recall bias, and adding patient and caregiver perspectives that clinician scales miss.
Community participation gaps look less like a question of patient willingness and more like a financing and infrastructure problem that no single bill has yet solved.
In today’s ACT Brief, we examine what changes when AI is embedded across clinical operations, why faster trial data isn’t yet producing faster decisions, and how FDA granted accelerated approval to a therapy for a rare airway disease.
Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
Trending on Applied Clinical Trials Online
1
Comparing OpenAI and Mistral on Clinical Trial Matching
2
Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health
3
From Complexity to Endpoint Meaningfulness: Addressing Key Neuroscience Trial Challenges with eCOA
4
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
5